IMNP Financials 07/16/2014 19:25:17 Immune Pharma

IMNP Financials 07/16/2014 19:25:17
Immune Pharmaceuticals Inc.
Period Ending Dec 31, 2013 Dec 31, 2012 Dec 31, 2011 Dec 31, 2010
Total Revenue 19 - 944 994
Cost of Revenue - - 692 997
Gross Profit 19 - 252 (3)
Operating Expenses
Research and Development 3,571 3,797 7,853 8,127
Sales, General and Admin. 5,448 5,395 6,452 7,244
Non-Recurring Items - - - -
Other - - - -
Operating Income (9,000) (9,192) (14,053) (15,374)
Income From Continuing Operations
Add'l Income/Expense Items 3,556 (3,336) (328) 202
Earnings Before Interest and Tax (5,444) (12,528) (14,381) (15,172)
Interest Expense 305 36 1,271 361
Earnings Before Tax (5,749) (12,564) (15,652) (15,533)
Income Tax 11 11 4 4
Minority Interest - - - -
Equity Earnings Unconsolidated Subsidiary - - - -
Net Income Cont. Operations (5,760) (13,124) (15,656) (15,537)
Non Recurring Events
Discontinued Operations - - - -
Extraordinary Items - - - -
Effect of Accounting Changes - - - -
Other Items - - - -
Net Income (5,760) (13,124) (15,656) (15,537)
Preferred Stock and Other Adjustments (932) - - -
Net Income Applicable to Common Shareholders (6,692) (12,575) (15,656) (15,537)